A multicenter, retrospective, real-world study of fingolimod in patients with relapsing remitting multiple sclerosis

Trial Profile

A multicenter, retrospective, real-world study of fingolimod in patients with relapsing remitting multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MS-MRIUS
  • Most Recent Events

    • 12 Dec 2017 Results assessing NEDA status in patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice, published in the CNS Drugs
    • 28 Oct 2017 Results of effects of fingolimod on brain atrophy presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results (n=571) assessing feasibility to measure brain atrophy presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top